KUMAMOTO University

R

研究実績RESEARCH ACHIEVEMENTS

  1. 1 .

    Zhao T, Coutts A, Xu L, Yu J, Ohshima K, Matsuoka M.

    HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBPα signaling.

    Retrovirology. 2013 Dec 21;10:159. doi: 10.1186/1742-4690-10-159. PMID: 24359396; PMCID: PMC3880043.

  2. 2 .

    Miura M, Yasunaga J, Tanabe J, Sugata K, Zhao T, Ma G, Miyazato P, Ohshima K, Kaneko A, Watanabe A, Saito A, Akari H, Matsuoka M.

    Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection.

    Retrovirology. 2013 Oct 24;10:118. doi: 10.1186/1742-4690-10-118. PMID: 24156738; PMCID: PMC4016002.

  3. 3 .

    Yuki H, Ueno S, Tatetsu H, Niiro H, Iino T, Endo S, Kawano Y, Komohara Y, Takeya M, Hata H, Okada S, Watanabe T, Akashi K, Mitsuya H, Okuno Y.

    PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.

    Blood. 2013 Feb 7;121(6):962-70. doi: 10.1182/blood-2012-05-431429. Epub 2012 Dec 4. PMID: 23212521.

  4. 4 .

    Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, Matsuoka M.

    HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression.

    PLoS Pathog. 2013 Sep;9(9):e1003630. doi: 10.1371/journal.ppat.1003630. Epub 2013 Sep 19. PMID: 24068936; PMCID: PMC3777874.

  5. 5 .

    Salcedo Gómez PM, Amano M, Yashchuk S, Mizuno A, Das D, Ghosh AK, Mitsuya H.

    GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

    Antimicrob Agents Chemother. 2013 Dec;57(12):6110-21. doi: 10.1128/AAC.01420-13. Epub 2013 Sep 30. PMID: 24080647; PMCID: PMC3837900.

  6. 6 .

    Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y, Ito M, Aihara K, An DS, Koyanagi Y.

    HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo.

    PLoS Pathog. 2013;9(12):e1003812. doi: 10.1371/journal.ppat.1003812. Epub 2013 Dec 5. PMID: 24339781; PMCID: PMC3855622.

  7. 7 .

    Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H.

    GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

    Antimicrob Agents Chemother. 2013 May;57(5):2036-46. doi: 10.1128/AAC.02189-12. Epub 2013 Feb 12. PMID: 23403426; PMCID: PMC3632947.

  8. 8 .

    Mizuhara T, Kato T, Hirai A, Kurihara H, Shimada Y, Taniguchi M, Maeta H, Togami H, Shimura K, Matsuoka M, Okazaki S, Takeuchi T, Ohno H, Oishi S, Fujii N.

    Structure-activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents.

    Bioorg Med Chem Lett. 2013 Aug 15;23(16):4557-61. doi: 10.1016/j.bmcl.2013.06.026. Epub 2013 Jun 19. PMID: 23845222.

  9. 9 .

    Kawano Y, Kikukawa Y, Fujiwara S, Wada N, Okuno Y, Mitsuya H, Hata H.

    Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.

    Int J Oncol. 2013 Dec;43(6):1809-16. doi: 10.3892/ijo.2013.2134. Epub 2013 Oct 10. PMID: 24126540; PMCID: PMC3834117.

  10. 10 .

    Shimane K, Kawaji K, Miyamoto F, Oishi S, Watanabe K, Sakagami Y, Fujii N, Shimura K, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

    HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

    Antimicrob Agents Chemother. 2013 Aug;57(8):4035-8. doi: 10.1128/AAC.00237-13. Epub 2013 May 20. PMID: 23689710; PMCID: PMC3719727.

  11. 11 .

    Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, Hata H.

    PDK1 inhibition is a novel therapeutic target in multiple myeloma.

    Br J Cancer. 2013 Jan 15;108(1):170-8. doi: 10.1038/bjc.2012.527. Epub 2012 Nov 29. PMID: 23321518; PMCID: PMC3553526.

  12. 12 .

    Togami H, Shimura K, Okamoto M, Yoshikawa R, Miyazawa T, Matsuoka M.

    Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents.

    J Virol. 2013 Apr;87(8):4322-9. doi: 10.1128/JVI.03208-12. Epub 2013 Jan 30. PMID: 23365453; PMCID: PMC3624392.

  13. 13 .

    Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

    High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.

    Eur J Haematol. 2013 Sep;91(3):201-8. doi: 10.1111/ejh.12155. Epub 2013 Jul 7. PMID: 23751147.

  14. 14 .

    Izumi K, Kawaji K, Miyamoto F, Shimane K, Shimura K, Sakagami Y, Hattori T, Watanabe K, Oishi S, Fujii N, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

    Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

    Int J Biochem Cell Biol. 2013 Apr;45(4):908-15. doi: 10.1016/j.biocel.2013.01.015. Epub 2013 Jan 26. PMID: 23357451; PMCID: PMC4136414.

  15. 15 .

    Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S.

    Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.

    Free Radic Biol Med. 2013 Dec;65:778-788. doi: 10.1016/j.freeradbiomed.2013.08.161. Epub 2013 Aug 20. PMID: 23973637.

  16. 16 .

    Ma G, Yasunaga J, Fan J, Yanagawa S, Matsuoka M.

    HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells.

    Oncogene. 2013 Sep 5;32(36):4222-30. doi: 10.1038/onc.2012.450. Epub 2012 Oct 8. PMID: 23045287.

  17. 17 .

    Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team.

    Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.

    PLoS One. 2013 Aug 8;8(8):e73639. doi: 10.1371/journal.pone.0073639. PMID: 23951362; PMCID: PMC3738570.

  18. 18 .

    Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S; Epzicom-Truvada study team.

    Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.

    Intern Med. 2013;52(7):735-44. doi: 10.2169/internalmedicine.52.9155. Epub 2013 Apr 1. PMID: 23545667.

  19. 19 .

    Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

    Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

    J Med Chem. 2013 Sep 12;56(17):6792-802. doi: 10.1021/jm400768f. Epub 2013 Aug 15. PMID: 23947685; PMCID: PMC3800042.

  20. 20 .

    Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H.

    P2′ benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.

    Antimicrob Agents Chemother. 2013 Oct;57(10):4920-7. doi: 10.1128/AAC.00868-13. Epub 2013 Jul 22. PMID: 23877703; PMCID: PMC3811474.

  21. 21 .

    Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

    Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethynyl-2-fluoro-2′-deoxyadenosine.

    Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64. doi: 10.1128/AAC.01703-13. Epub 2013 Oct 7. PMID: 24100493; PMCID: PMC3837839.

  22. 22 .

    Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

    Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.

    Retrovirology. 2013 Jun 24;10:65. doi: 10.1186/1742-4690-10-65. PMID: 23800377; PMCID: PMC3695782.

  23. 23 .

    Hachiya A, Reeve AB, Marchand B, Michailidis E, Ong YT, Kirby KA, Leslie MD, Oka S, Kodama EN, Rohan LC, Mitsuya H, Parniak MA, Sarafianos SG.

    Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs.

    Antimicrob Agents Chemother. 2013 Sep;57(9):4554-4558. doi: 10.1128/AAC.00283-13. Epub 2013 Jun 24. PMID: 23796932; PMCID: PMC3754316.

  24. 24 .

    Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel PA, Mitsuya H, Kessl JJ, Engelman A, Fuchs JR, Kvaratskhelia M.

    The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.

    J Biol Chem. 2013 May 31;288(22):15813-20. doi: 10.1074/jbc.M112.443390. Epub 2013 Apr 24. PMID: 23615903; PMCID: PMC3668738.

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.